Table 1 FDA approved tumor-therapeutic antibodies [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]

Rituximab (Rituxan)

IgG1

CD20

NHL

ADCC/CDC

[2]

Trastuzumab (Herceptin)

IgG1

Her2

Breast cancer

Growth signal blocking; ADCC

[3, 4]

Cetuximab (Erbitux)

IgG1

EGFR

mCRC

Growth signal blocking; ADCC

[5]

Bevacizumab

IgG1

VEGF

Solid tumors

Angiogenesis inhibition

[6]

Panitumumab (Vectibix)

IgG2

EGFR

mCRC

Growth signal blocking

[7]

Ofatumumab (Arzerra)

IgG1

CD20

CLL

ADCC/CDC

[8]

Alemtuzumab (Campath)

IgG1

CD52

CLL

ADCC/CDC

[9]

Denosumab (Xgeva)

IgG1

RANKL

Bone tumor

Growth signal blocking

[10]

Ipilimumab (Yervoy)

IgG1

CTLA-4

Solid tumors

Depleting Treg cells

[11, 12]

Pertuzumab (Perjeta)

IgG1

Her2

Breast cancer

Growth signal blocking

[13]

Obinutuzumab (Gazyva)

IgG1

CD20

CLL

ADCC; apoptosis induction

[14]

Ramucirumab (Cyramza)

IgG1

VEGFR2

Solid tumors

Angiogenesis inhibition

[15]

Pembrolizumab (Keytruda)

IgG4

PD-1

Solid tumors

Neutralizing inhibitory signal in T cells

[16]

Nivolumab (Opdivo)

IgG4

PD-1

Solid tumors

Neutralizing inhibitory signal in T cells

[17]

Dinutuximab (Unituxin)

IgG1

GD2

Neuroblastoma

ADCC/CDC

[18]

Daratumumab (Darzalex)

IgG1

CD38

Multiple myeloma

ADCC/CDC; apoptosis induction

[19]

Elotuzumab (Empliciti)

IgG1

SLAMF7

Multiple myeloma

ADCC,direct activation

of NK cells

[20]

Atezolizumab (Tecentriq)

IgG1

PD-L1

Solid tumors

Neutralizing inhibitory signal in T cells

[21]

Avelumab (Bavencio)

IgG1

PD-L1

Solid tumors

Neutralizing inhibitory signal in T cells; ADCC

[22]

Durvalumab (Imfinzi)

IgG1

PD-L1

Solid tumors

Neutralizing inhibitory signal in T cells

[21]

Mogamulizumab (Poteligeo)

IgG1

CCR4

CTCL

ADCC

[23]

Cemiplimab (Libtayo)

IgG4

PD-1

Solid tumors

Neutralizing inhibitory signal in T cells

[24]